Author

A. Eggermont

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

E. Sanders· 2 shared F. Speleman· 2 shared F. Van Nieuwerburgh· 2 shared K. Durinck· 2 shared L. Delhaye· 2 shared L. Depestel· 2 shared L. Tilleman· 2 shared P. Van Vlierberghe· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Sanders

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The fork restart factor PHF6 interacts with RRM2 and binds to H3K56ac marked nascent DNA

L. Depestel, S.-L. Bekaert, E. Sanders, C. Van Damme, A. Eggermont, S. Loontiens, L. Tilleman, F. Van Nieuwerburgh, L. Delhaye, P. Van Vlierberghe, S. Eyckerman, F. Speleman, K. Durinck

This study identifies PHF6's interaction with RRM2 and its binding to H3K56ac marked nascent DNA, revealing a role in replication fork restart and DNA damage repair.

bioRxiv · Mar 8, 2023 · PreprintCancer Biology

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

C. Nunes, L. Depestel, L. M. Mus, K. M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, E. M. Dolman, V. Olexiouk, C. Bartenhagen, F. Devloed, E. Sanders, A. Eggermont, J. Van Laere, E. De Smet, , F. Speleman

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

bioRxiv · Nov 25, 2020 · PreprintCancer Biology